No Data
No Data
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Merck & Company (MRK)
Expert Outlook: ResMed Through The Eyes Of 9 Analysts
Across the recent three months, 9 analysts have shared their insights on ResMed (NYSE:RMD), expressing a variety of opinions spanning from bullish to bearish.The table below offers a condensed view of
ResMed Price Target Maintained With a $215.00/Share by Mizuho
ResMed Price Target Maintained With a $215.00/Share by Mizuho
ResMed Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 10.13% Mizuho $215 → $215 Maintains Buy 02/06/2024 16.28% Keybanc → $227 Initiates Coverage On
Here's Why I Think the Resmed Share Price Should Be 18% Higher
Peering Into ResMed's Recent Short Interest
ResMed's (NYSE:RMD) short percent of float has risen 4.07% since its last report. The company recently reported that it has 6.58 million shares sold short, which is 5.11% of all regular shares that ar
No Data